3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Interventions
pembrolizumab
2
Imatinib Mesylate
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
tislelizumab
1
regorafenib
1
gallium 68 PSMA-11
1
avelumab
1
Tretinoin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
GSK-3326595
1
Everolimus
1
Etoposide
1
Endoscopic Mucosal Resection
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Adenoid Cystic
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts